Novo Nordisk Q3 2026: What the Wegovy Pill Means for Investors

The Wegovy pill strengthens Novo Nordisk’s recovery, but it does not make the stock a straightforward turnaround bet. Third-quarter 2026 results combine growing treatment volumes and higher guidance with a sharp divide between adjusted and reported earnings.

As of 5 November 2026, based on results released on 4 November.

Novo Nordisk Q3 earnings: What actually improved?

Third-quarter revenue reached DKK 79.195 billion, up 6% in Danish kroner and 4% at constant exchange rates. Those growth rates are not interchangeable: currency movements do not represent additional medicines sold or stronger pricing power.

Adjusted operating profit was DKK 31.720 billion, increasing 27% at constant exchange rates. Novo also raised its full-year outlook. It now expects both adjusted sales growth and adjusted operating profit growth to range from minus 2% to plus 2% at constant exchange rates, compared with the previous range of minus 6% to zero.

That is a meaningful improvement in expectations. It is not yet evidence that the whole company has returned to sustained high growth. An outlook centred around broadly flat performance tells a different story from an uninterrupted growth boom.

Why the oral Wegovy launch matters

The Wegovy pill generated DKK 5.394 billion in quarterly revenue. By the end of the quarter it had launched in the United States, the United Arab Emirates, the United Kingdom and Germany. Four more launches brought the total to eight markets by the results announcement.

An oral treatment could appeal to people reluctant to use injections, potentially broadening the addressable market. However, the commercial opportunity depends on more than patient preference. Reimbursement, out-of-pocket costs and how long patients remain on treatment all influence the value of each new customer.

For investors, the key distinction is between product revenue and genuinely incremental group revenue. If an existing patient switches from another Novo treatment to the pill, some sales simply move between products. A stronger investment case requires additional patients and attractive incremental profit after discounts, manufacturing and selling costs.

Why 27% adjusted profit growth needs context

The comparison with last year is unusually favourable. Novo recognised DKK 9 billion of company-wide transformation costs in the third quarter of 2025. A comparison against a quarter burdened by restructuring can make the subsequent growth rate look particularly strong.

The current quarter also contains substantial adjustments. Reported operating profit was DKK 23.011 billion, down 9% at constant exchange rates. Novo recognised DKK 8.7 billion of non-cash impairment charges: DKK 4.6 billion related to ziltivekimab and DKK 4.1 billion related to resizing its manufacturing network.

Adjusted and reported profit therefore answer different questions. The adjusted figure helps assess ongoing trading; the reported number also captures consequences of earlier spending decisions. Both deserve attention. Non-cash does not mean economically irrelevant: an impairment can signal that previously invested capital will deliver less value than originally expected.

Neither figure should be read in isolation. Treating every adjustment as routine business would obscure the underlying recovery, but ignoring every write-down would make capital allocation disappear from the investment analysis.

Volume growth is not the same as pricing power

Novo attributed growth to higher GLP-1 volumes across its US and international operations, partly offset by lower realised prices. That trade-off is central to the next stage of the recovery.

When net revenue per treatment declines, additional volume must first offset the price reduction. New markets and improved availability may help, but broader reimbursement and greater access can also come with commercial concessions. A large potential patient population does not automatically produce attractive shareholder returns.

The useful question is therefore not simply whether prescriptions are rising. It is whether volume, product mix and net prices together support durable profits after research, distribution and manufacturing costs. More boxes leaving a factory can be excellent news. The price paid for them still matters.

Cash flow and manufacturing are the second reality check

For the full year, Novo now expects capital expenditure of approximately DKK 50 billion and free cash flow, under its own definition, of DKK 60–70 billion. These remain forecasts rather than completed annual outcomes.

The combination of heavy investment and manufacturing impairments highlights a practical challenge: capacity is not universally interchangeable. A changing mix of oral and injectable products can alter which facilities are most valuable. An asset that made sense under one demand forecast may be less productive under another.

Stronger free cash flow would be encouraging, but its source matters. Lower capital spending can improve near-term cash generation without necessarily demonstrating stronger underlying demand. The durable outcome is adequate capacity for products patients actually use, achieved without repeatedly writing down yesterday’s investment plans.

What would confirm—or undermine—the recovery?

The constructive scenario is an expanding pill business that reaches additional patients while preserving attractive economics across the wider portfolio. Resilient adjusted margins and understandable cash conversion would support that interpretation.

The weaker scenario is rapid pill adoption that mostly shifts existing sales between Novo products, while discounting and launch costs limit incremental profit. Further development setbacks or capacity reductions could then expose the difference between selling more medicine and earning a satisfactory return on capital.

Valuation should reflect both possibilities. A seemingly low price-to-earnings ratio is less useful when its earnings denominator contains major exceptional items. Our guide to fair value and stock valuation explains how changing earnings and cash-flow assumptions affect the investment case. A precise price target would require a separate, explicit valuation model rather than an extrapolation of one quarter’s growth.

Five questions for the next earnings reports

• Is oral growth bringing in additional patients or primarily replacing existing treatments?
• How are realised prices changing alongside treatment volumes?
• Can adjusted operating margins hold up once the favourable comparison base fades?
• Do reported and adjusted earnings begin to converge?
• Are capital spending, capacity utilisation and free cash flow consistent with one another?

The SmartDeer view

These results make a recovery more credible, not inevitable. The important achievement would be more than a successful pill launch: it would be a repeatable business with incremental demand, sustainable net pricing and productive investment. That is the bridge between a good earnings headline and a durable long-term investment thesis.

Not investment advice or medical advice. This article is provided solely for information and analysis.